{"id":2574,"date":"2018-03-08T10:02:39","date_gmt":"2018-03-08T04:32:39","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2574"},"modified":"2023-06-16T11:07:37","modified_gmt":"2023-06-16T05:37:37","slug":"transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-market","title":{"rendered":"Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/familial-amyloid-polyneuropathy-transthyretin-amyloidosis-corino-de-andrades-disease-market\"><strong>Transthyretin Amyloidosis<\/strong><\/a> (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. The number of Diagnosed Prevalent Population of Transthyretin Amyloidosis was estimated to be around <strong>19,160 cases<\/strong> in 2016. Out of all the diagnosed cases, the number of treatable cases of Transthyretin Amyloidosis was around <strong>9,545 cases<\/strong> in 2016. Region-wise market size analysis of the indication has shown that among 7MM US accounts for the highest market size, followed by EU5 and Japan.<\/p>\n\n\n\n<p>The therapeutic market of Transthyretin Amyloidosis was estimated to be around <strong>USD 922 million<\/strong> in 7MM in 2016. <strong>Vyndaqel<\/strong> (tafamidis meglumine) by <strong>Pfizer<\/strong> is the only approved therapy for the treatment of Transthyretin <a href=\"https:\/\/www.delveinsight.com\/report-store\/familial-amyloid-polyneuropathy-epidemiology-forecast\">Familial Amyloid Polyneuropathy<\/a> (TTR-FAP) in adult patients with stage 1 symptomatic Polyneuropathy in Europe and for all stages in Japan. The market is expected to grow significantly with the launch of upcoming drugs: <strong>Patisiran<\/strong> (Alnylam Pharmaceuticals) and <strong>Inotersen<\/strong> (Ionis Pharmaceuticals Inc.) in 2018 and <strong>CRX-1008<\/strong> (Corino Therapeutics Inc) in 2023.<\/p>\n\n\n\n<p>The report has covered approximately <strong>15 pipeline<\/strong> products out of which around <strong>8<\/strong> are in the clinical development phase. Detailed historical and forecasted market analysis covering 7MM from 2015-2027 has been provided. Market size by therapy covering 7MM is provided to better understand the market distribution and major players. Historical, as well as the forecasted epidemiology of the disease in the 7MM covering all the major details of the indication, is provided.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. The number of Diagnosed Prevalent Population of Transthyretin Amyloidosis was estimated to be around 19,160 cases in 2016. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[1482,1479,1118,180,1330,1484,204,1478,1319,1483,1437,379,381,1326,460,845,706,1476,1481,1480],"industry":[17225],"therapeutic_areas":[17238,17234],"class_list":["post-2574","post","type-post","status-publish","format-standard","hentry","category-articles","category-facts-and-figures","tag-alnylam-pharmaceuticals","tag-attr","tag-business-research","tag-competitive-landscape","tag-corino-therapeutics","tag-crx-1008","tag-delveinsight","tag-epidemiology-and-market","tag-familial-amyloid-polyneuropathy","tag-inotersen","tag-ionis-pharmaceuticals","tag-market-insights","tag-market-research","tag-patisiran","tag-pfizer","tag-pharma-market","tag-pharmaceutical-industry","tag-prevalent","tag-tafamidis-meglumine","tag-vyndaqel","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Transthyretin Amyloidosis (ATTR) - Pharma Market Report<\/title>\n<meta name=\"description\" content=\"According to Delveinsight, the therapeutic market of Transthyretin Amyloidosis was estimated to be around USD 922 million in 7MM in 2016.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transthyretin Amyloidosis (ATTR) - Pharma Market Report\" \/>\n<meta property=\"og:description\" content=\"According to Delveinsight, the therapeutic market of Transthyretin Amyloidosis was estimated to be around USD 922 million in 7MM in 2016.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-08T04:32:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-16T05:37:37+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Transthyretin Amyloidosis (ATTR) - Pharma Market Report","description":"According to Delveinsight, the therapeutic market of Transthyretin Amyloidosis was estimated to be around USD 922 million in 7MM in 2016.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-market","og_locale":"en_US","og_type":"article","og_title":"Transthyretin Amyloidosis (ATTR) - Pharma Market Report","og_description":"According to Delveinsight, the therapeutic market of Transthyretin Amyloidosis was estimated to be around USD 922 million in 7MM in 2016.","og_url":"https:\/\/www.delveinsight.com\/blog\/transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-03-08T04:32:39+00:00","article_modified_time":"2023-06-16T05:37:37+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-market","url":"https:\/\/www.delveinsight.com\/blog\/transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-market","name":"Transthyretin Amyloidosis (ATTR) - Pharma Market Report","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2018-03-08T04:32:39+00:00","dateModified":"2023-06-16T05:37:37+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"According to Delveinsight, the therapeutic market of Transthyretin Amyloidosis was estimated to be around USD 922 million in 7MM in 2016.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/transthyretin-amyloidosis-attr-competitive-landscape-market-insights-epidemiology-market"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">ATTR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Corino Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">CRX-1008<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Epidemiology and Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Familial Amyloid Polyneuropathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Inotersen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Ionis pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Market insights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Patisiran<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">pharma market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">prevalent<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">tafamidis meglumine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Vyndaqel<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">ATTR<\/span>","<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">Corino Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">CRX-1008<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Epidemiology and Market<\/span>","<span class=\"advgb-post-tax-term\">Familial Amyloid Polyneuropathy<\/span>","<span class=\"advgb-post-tax-term\">Inotersen<\/span>","<span class=\"advgb-post-tax-term\">Ionis pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Market insights<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">Patisiran<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma market<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">prevalent<\/span>","<span class=\"advgb-post-tax-term\">tafamidis meglumine<\/span>","<span class=\"advgb-post-tax-term\">Vyndaqel<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Mar 8, 2018","modified":"Updated on Jun 16, 2023"},"absolute_dates_time":{"created":"Posted on Mar 8, 2018 10:02 am","modified":"Updated on Jun 16, 2023 11:07 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2574"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2574\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2574"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2574"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}